Fermenta Biotech Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹156Cr
- +58.1% YoY
- +64.7% QoQ
- Net profit
- ₹38Cr
- +279.3% YoY
- +240.7% QoQ
- Margin
- 34.04%
- +8.6 pp YoY
- +14.3 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Fermenta Biotech Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q3-FY25 consolidated operational revenue: INR 1,565 Mn, up 58.1% YoY (Page 12) - Q3-FY25 standalone operational revenue: INR 1,463 Mn, up 63.6% YoY (Page 10) - Q3-FY25 revenue excluding real estate: I Q3-FY25 Consolidated Financials: - Operational EBITDA: INR 533 Mn (vs INR 252 Mn in Q3-FY24), showing strong YoY growth - Operational EBITDA Margin: 34.06% (vs 25.45% in Q3-FY24), an increase of
From Fermenta Biotech Ltd's Q3 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3-FY25 consolidated operational revenue: INR 1,565 Mn, up 58.1% YoY (Page 12)
- Q3-FY25 standalone operational revenue: INR 1,463 Mn, up 63.6% YoY (Page 10)
- Q3-FY25 revenue excluding real estate: INR 118 crore (~INR 1,180 Mn), up 105% YoY (Page 8)
- Human Nutrition volume growth: 102% over Q3-FY24 (Page 8)
- Animal Nutrition volume growth: 4% over Q3-FY24 (Page 8)
- 9M-FY25 consolidated operational revenue: INR 3,296 Mn, up 38.3% YoY (Page 13)
2 more points from Fermenta Biotech Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Fermenta Biotech Ltd said on order book & pipeline — free account, 30 seconds.
Fermenta Biotech Ltd — Quarterly revenue & net profit
Fermenta Biotech Ltd Q3 FY25 results — key figures
| ₹ Cr | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 156 | 99 | +58.1% | 95 | +64.7% |
| Operating profit (EBITDA) | 53 | 25 | +112% | 19 | +183.7% |
| Operating margin | 34.04% | 25.39% | +8.6 pp | 19.76% | +14.3 pp |
| Profit before tax | 45 | 16 | +182% | 12 | +283.6% |
| Net profit (PAT) | 38 | 10 | +279.3% | 11 | +240.7% |
| EPS (₹) | 12.54 | 3.35 | +274.3% | 3.87 | +224% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹133 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fermenta Biotech's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharmaceuticals (Q3 FY25)
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Wockhardt (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- NGL Fine Chem (Q3 FY25)
Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3 FY25…
- Shree Ganesh Rem (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Fermenta Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Fermenta Biotech Ltd Q3 FY25 results?
Q3-FY25 consolidated operational revenue: INR 1,565 Mn, up 58.1% YoY (Page 12) - Q3-FY25 standalone operational revenue: INR 1,463 Mn, up 63.6% YoY (Page 10) - Q3-FY25 revenue excluding real estate: I Q3-FY25 Consolidated Financials: - Operational EBITDA: INR 533 Mn (vs INR 252 Mn in Q3-FY24), showing strong YoY growth - Operational EBITDA Margin: 34.06% (vs 25.45% in Q3-FY24), an increase of
What is Fermenta Biotech Ltd share price analysis?
Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
